Mitochondrial-derived peptides in energy metabolism
- 10 August 2020
- journal article
- review article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 319 (4) , E659-E666
Abstract
Mitochondrial-derived peptides (MDPs) are small bioactive peptides encoded by short open-reading frames (sORF) in mitochondrial DNA that do not necessarily have traditional hallmarks of protein-coding genes. To date, eight MDPs have been identified, all of which have been shown to have various cyto- or metaboloprotective properties. The 12S ribosomal RNA ( MT-RNR1) gene harbors the sequence for MOTS-c, whereas the other seven MDPs [humanin and small humanin-like peptides (SHLP) 1–6] are encoded by the 16S ribosomal RNA gene. Here, we review the evidence that endogenous MDPs are sensitive to changes in metabolism, showing that metabolic conditions like obesity, diabetes, and aging are associated with lower circulating MDPs, whereas in humans muscle MDP expression is upregulated in response to stress that perturbs the mitochondria like exercise, some mtDNA mutation-associated diseases, and healthy aging, which potentially suggests a tissue-specific response aimed at restoring cellular or mitochondrial homeostasis. Consistent with this, treatment of rodents with humanin, MOTS-c, and SHLP2 can enhance insulin sensitivity and offer protection against a range of age-associated metabolic disorders. Furthermore, assessing how mtDNA variants alter the functions of MDPs is beginning to provide evidence that MDPs are metabolic signal transducers in humans. Taken together, MDPs appear to form an important aspect of a retrograde signaling network that communicates mitochondrial status with the wider cell and to distal tissues to modulate adaptative responses to metabolic stress. It remains to be fully determined whether the metaboloprotective properties of MDPs can be harnessed into therapies for metabolic disease.Keywords
Funding Information
- Rutherford Discover Fellowship (RDF-15-UOA-020)
- NIA (R01AG052258)
- Hanson-Thorell Family (N/A)
- American Federation for Aging Research (N/A)
- Ellison Medical Foundation (N/A)
- Royal Society of New Zealand | Marsden Fund (16-UOA-313)
This publication has 59 references indexed in Scilit:
- Circulating humanin levels are associated with preserved coronary endothelial functionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient miceLife Sciences, 2012
- Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stressCardiovascular Research, 2010
- The neurosurvival factor Humanin inhibits β-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic miceMetabolism, 2010
- Humanin: A Novel Central Regulator of Peripheral Insulin ActionPLOS ONE, 2009
- Neuroprotective effect of humanin on cerebral ischemia/reperfusion injury is mediated by a PI3K/Akt pathwayBrain Research, 2008
- Identification of Mitochondrial DNA Polymorphisms That Alter Mitochondrial Matrix pH and Intracellular Calcium DynamicsPLOS Genetics, 2006
- Humanin expression in skeletal muscles of patients with chronic progressive external ophthalmoplegiaJournal of Human Genetics, 2006
- Effect of humanin on decreased ATP levels of human lymphocytes harboring A3243G mutant mitochondrial DNANeuropeptides, 2005
- Humanin peptide suppresses apoptosis by interfering with Bax activationNature, 2003